Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

U.S. to invest another $1 billion in rapid COVID-19 tests

Published 10/06/2021, 04:28 PM
Updated 10/06/2021, 04:46 PM
© Reuters. FILE PHOTO: A used coronavirus disease (COVID-19) rapid test with negative result is pictured during pandemic lockdown, in Berlin, Germany, March 31, 2021. REUTERS/Fabrizio Bensch/File Photo

By Carl O'Donnell and Alexandra Alper

(Reuters) -The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday.

The combined purchases will help quadruple the United States' test output by December to around 200 million tests per month, Jeff Zients, the White House coronavirus response coordinator, said during a press call.

"We'll continue to pull every lever to expand manufacturing production of tests which will have the impact of driving down the cost per test and making sure that tests are widely available and convenient," Zients said.

The government will also double the number of pharmacies it partners with to provide free COVID-19 tests to 20,000 pharmacies, Zients added.

Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs.

The White House in September said it plans to mandate weekly testing for unvaccinated staff at businesses with more than 100 employees.

The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories (NYSE:ABT) and Celltrion Inc to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests.

The U.S. government also has agreements to purchase tests from other manufacturers, including Quidel (NASDAQ:QDEL) Corp., OraSure Technologies, and Intrivo.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Earlier this week, U.S. regulators authorized another rapid test from Acon Technologies that can be taken at home. Zients said the test will retail for around $10 per test.

The average number of daily U.S. coronavirus cases dropped by 12% over the last seven days to nearly 98,000, and hospitalizations dropped 14% to 7,400, said U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky said during the briefing.

She cautioned that deaths remained constant at 1,400 per day.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.